NCT02485015View on ClinicalTrials.gov

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2030

Study Completion Date

June 30, 2033

Conditions
Stomach Neoplasms
Interventions
BIOLOGICAL

Cytokine-Induced Killer Cells

Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.

DRUG

Apatinib

Advanced gastric cancer patients take Apatinib 850mg qd by mouth.

All Listed Sponsors
lead

The First People's Hospital of Changzhou

OTHER